Introduction
The 26th Conference on Retroviruses and Opportunistic Infections 2019 meeting (CROI
2019) took place on 4–9 March in Seattle, WA, USA. This meeting provides up-to-date
information of outstanding quality on HIV prevention, treatment and cure research
as well as comorbidities.
The case of viraemia remission over 18 months after antiretroviral therapy (ART) discontinuation
in a patient who had received stem cell transplantation, otherwise known as the ‘London
Patient‘, was one of the highlights of the meeting and produced much excitement among
attendees and the international press. There was ongoing new data regarding the issue
of potential teratogenicity with integrase inhibitors as raised in May 2018 in a cohort
in Botswana. Impressive novel preventative and therapeutic agents and options for
HIV were also presented together with important issues in terms of clinical management,
opportunistic infections, sexually transmitted infections and comorbidities such as
ageing, cognitive dysfunction and weight gain.
HIV-1 cure
There were two reports of control of viraemia after stem cell transplantation, the
so-called ‘London Patient’ and a Dusseldorf patient [1,2] with delayed viral rebound
during analytic treatment interruption (ATI) after infusion of CCR5 ZFN-treated CD4
T cells [3]. A report of ex vivo and in vivo editing of SIV genome in non-human primates
by CRISPR-Cas9 [4] and a study using multidose IV romidepsin with no increased HIV-1
expression in persons on antiretroviral therapy (ART) (ACTG A5315)[5] were also presented.
The two cases of control of viraemia after discontinuation of antiretroviral therapy
(ART) were described and included viraemia control for 18 months in the ’London Patient’
after lymphoma treated with chemotherapy and a stem cell transplant from a homozygous
CCR5Δ32 donor and for 3 months in a patient similarly treated in Dusseldorf for leukaemia,
both with relatively low-level conditioning before stem cell transplant [1,2]
. These case-reports confirm the fact that the ‘Berlin patient’ who had remained the
only patient cured with similar intervention was not an isolated case in terms of
viral remission after such an intervention; however, a longer follow-up is needed
to be able to conclude on a cure. Although this improves our understanding of the
importance of the CCR5 receptor in viral rebound, the great limitation of this process
is that it is not easily generalised.
The open-label, pilot three-arm study by Tebas and colleagues presented on zinc finger
nuclease (ZFN) gene therapy with ex vivo treatment of CD4+ T cells with CCR5 ZFN using
RNA-based transfection (RNA encoding ZFN SB 728) with or without a single dose cyclophosphamide
[3]
. Individuals were well controlled in terms of HIV infection. One infusion of modified
cells resulted in about 25% of disrupted CCR5, with an impact on the percentage of
cells with cyclophosphamide with a potential delay in viral rebound post-ART interruption.
A new approach aimed at integrated SIV at LTR and gag was presented by Burdo and colleagues
using CRISPR-Cas9 ex vivo and in vivo SIV genome editing in non-human primates. Results
showed SIV cleavage in vitro in PBMCs and excellent biodistribution of these edited
SIV genomes in tissues [4].
The ACTG trial A5315 reported by McMahon and colleagues was disappointing as it showed
no increase in plasma viraemia after multi doses of romidepsin, an HDAC inhibitor,
given intravenously [5]. There were no changes when either using a single-copy assay
or cell-associated DNA or RNA measurements. This is part of the’ kick and kill’ strategy,
which has also used other HDAC inhibitors. The use of romidepsin in this study did
not raise safety concerns.
Broadly neutralising antibodies and their potential use in cure research use is reviewed
below.
Antiretroviral agents against HIV-1
in development
There is continuing drug development with exciting new compounds active against multi-resistant
viruses, long-acting activity and a potential broadening of their impact on the immune
system.
The novel nucleoside produced by Merck, MK8591 (EFdA) inhibits reverse transcription
and translocation. It is potent and active against multiple resistant strains. Its
long half-life may allow weekly dosing [6]. It is currently in a Phase 2 clinical
trial (NCT03272347) for the treatment of HIV-1 infection with once-daily administration
of 0.25, 0.75, or 2.25 mg in combination with doravirine.
The first in class HIV-1 capsid function inhibitor, GS-6207, developed by Gilead has
potent antiviral activity also in multiclass resistant virus and low predicted human
clearance and aqueous solubility. It is of great interest due to the fact that parenteral
administration could be given infrequently. It was reported at this meeting that this
agent acts early but also late in the virus life cycle [7]. This Phase I study evaluated
safety, tolerability and pharmacokinetics. Data in healthy volunteers (four cohorts)
receiving different dosing such 30, 100, 300 and 450 mg subcutaneously shows that
with a single dose of at least 100 mg levels above EC95 are maintained for more than
12 weeks. There were no serious side-effects reported. Based on interim data it was
well-tolerated as a single dose administered subcutaneously in healthy subjects and
supported a dosing interval of at least 3 months. [8].
DeJesus and colleagues presented results from a 10-day Phase 2a, dose-finding study
for the GSK maturation inhibitor, GSK2838232, in 33 participants. Binding to gag,
it targets late-stage viral life-cycle. This new compound, which follows the discontinuation
of two previous maturation inhibitors, has good potency and broad activity. It has
shown good tolerability. The two-part study presented used 150-mg cobicistat boosting.
Doses tested were 20, 50, 100 and 200 mg once daily in participants with mean CD4
cell counts of 540 cells/mm3 and 58,000 HIV-1 copies/mL. Mean viral load decrease
was 1.5 log10 for the 200-mg dose at 10 days and 1.2 log10 in the 50- and 100-mg doses.
The available resistance data show genotypic changes at A364A/W in gag
[9].
There is a need for the development of new compound with activity against NRTI resistance.
The NRTI candidate GS-9131, with potent activity against HIV-1 virus with NRTI resistance,
has a broad activity against HIV-1 subtypes. It is a monoaminate prodrug of the nucleotide
analogue GS-9148, which acts through chain termination, with low potential for mitochondrial
and renal toxicity and activity against major NRTI resistance [10].
A long-acting (LA) combination is a very important development in HIV-1 treatment.
At this meeting two studies, FLAIR and ATLAS, were presented on the LA combination
of cabotegravir (CAB) and the non-nucleoside reverse transcriptase inhibitor (NNRTI)
rilpivirine (RPV), which were shown to maintain virological suppression [11,12].
The FLAIR study, a Phase 3, open-label, randomised controlled trial in ART-naïve adult
participants aimed to establish whether virological suppression in participants on
an integrase inhibitor single-tablet regimen abacavir/dolutegravir/lamivudine (ABC/DTG/3TC)
continued after participants switched to LA CAB/RPV by intramuscular administration
every 4 weeks and its safety. The primary end-point was at 48 weeks and aimed at showing
non-inferiority compared to the oral comparator. There were 566 naïve individuals
to ART who started on ABC/DTG/3TC. Participants undetectable at 20 weeks were randomised
to continue the regimen or switch to short-acting CAB/RPV followed by LA CAB/RPV [11].
The ATLAS study evaluated efficacy, safety and tolerability of switching to LA CAB/RPV
from current antiretroviral regimen in virologically suppressed adults with HIV-1.
There were 616 virologically suppressed individuals on PI, NNRTI and integrase inhibitors
regimens. Participants either remained on their regimen or were switched to oral CAB/RPV
for 4 weeks followed by LA CAB/RPV for 48 weeks. In both studies the combination was
shown to be well-tolerated with few discontinuations and non-inferiority was demonstrated
[11,12].
A new generation of potent, broadly neutralising antibodies (bNAbs) is being developed.
bNAbs are of great interest as preventative, therapeutic and cure agents as they show
antiviral potency coupled with the potential to activate immune responses that may
also be of importance in cure strategies. However, development of resistance when
they are used as single agents for treatment is leading to the combination of these
agents along with testing with the addition with other immunomodulators such as the
oral toll-like receptor 7 (TLR7) agonist GS-9620.
PGT121 is an IgG1 monoclonal antibody (Ab) targeting the V3 envelope and has potent
neutralising capacity against 60–70% of all HIV-1 strains. It had been tested in preventative
and therapeutic studies in non-human primates showing in association with GS-9620
control of viraemia without ART initiation. At this conference the first human Phase
I study was presented by Kathryn Stephenson. PGT121 was tested in individuals with
HIV-1 and on ART and in individuals without HIV-1. The study had a dose-escalating
first phase with PGT121 administered as a single infusion at 3, 10, and 30 mg/kg and
also subcutaneously at 3 mg/kg. This was followed by an open-label phase where PGT121
was given as a 30-mg/kg infusion to viraemic adults not on ART with either a high
or low HIV-1 viral load in a small cohort of patients. A few participants in the low
viral load arm showed long-term viral suppression. It was safe, with good tolerability
and a good pharmacokinetic (PK) profile. Its impact on host immunity is under investigation
[13].
The novel compound, GS-9722, is described as a first in-class, effector-enhanced bNab
for HIV cure. It is targeted at eliminating latently infected cells. Compared with
PGT121, it has been shown to have the same neutralisation breadth and potency but
has improved drug-like properties, less risk of immunogenicity, enhanced effector
function and optimised PK function. It is planned to use it in combination with other
bNAbs [14].
The presentation by Pegu and colleagues of a trispecific broadly neutralising antibody
compound with potent antiviral activity is a very exciting development. Combination
of antibodies is aimed at preventing development of resistance to HIV-1. These antibodies
interact with the CD4 binding site, membrane proximal external region (MPER) and V1V2
glycan which should lead to enhanced neutralisation. They have an intact IgG1 backbone.
Potent Fc effector functions in animal studies are promising for mediating ADCC and
phagocytosis [15,16]. Trispecific HIV broadly neutralising antibodies demonstrate
potent neutralisation and antibody-dependent cellular cytotoxicity (ADCC) in vitro,
and mediate antiviral activity in vivo.
Second- and third-line antiretroviral therapy
With widespread use of integrase inhibitors and the presence of resistance, various
studies were presented to clarify the efficacy of second-generation integrase inhibitors
in this situation.
The DAWNING study is a non-inferiority, randomised, Phase 3b, open-label study conducted
to evaluate the safety and efficacy of DTG and two NRTIs compared with lopinavir/ritonavir
(LPV/r) and two NRTIs in participants whose first-line ART of an NNRTI plus two NRTIs
was failing. Dolutegravir has been shown previously to be superior to LPV/r in a comparison
of a DTG-based regimen versus the WHO-recommended second-line regimen [17]. The presentation
showed that the advantage of the DTG-based regimen over that of the LPV/r-based regimens,
where both included at least one fully active NRTI, persisted regardless of baseline
NRTI resistance in a post hoc analysis. The M184V mutation was present in the majority
of patients and in isolation in 25%, and when present in an individual, DTG outperformed
LPV/r. The K65R mutation was present in 30% of participants while 24% had at least
one thymidine-analogue mutation. TDF and zidovudine were included in the baseline
regimens for some participants with these mutations and high responses were observed
in the DTG arm although participant numbers were
small [18].
The ongoing Phase 3 randomised, double-blinded GS 4030 study, which has enrolled 565
participants, is looking into well-controlled patients with documented baseline resistance
to any drug classes except integrase inhibiters. Randomisation involved staying on
a DTG with tenofovir or TAF/FTC regimen or a switch 1:1 to bictegravir (BIC)/FTC/TAF
for 48 weeks. In total, 82% (462/565) of participants had pre-switch genotypic data
available. Planned interim analysis (12 weeks of follow-up) showed a high rate of
baseline NRTI resistance (24%) with 99% of participants with HIV-1 viral load <50
copies/mL. Primary NNRTI and protease inhibitor (PI) resistance mutations were present
in 24% and 8% of participants, respectively. Pre-existing integrase inhibitor mutations
were found in 5% of participants [19].
Andreatta and colleagues from Gilead presented resistance and virological data on
long-term BIC/FTC/TAF efficacy from studies 1844 and 1878 on 2 year-open-label BIC/FTC/TAF
in patients with archived resistance [20]. Pre-existing primary NRTI (16%), NNRTI
(21%) and a low level of integrase level resistance (1.9%) were detected. No further
development of resistance was noted at the time of analysis with maintenance of virological
control.
Santoro and colleagues looked into another aspect of pre-existing resistance with
second-generation integrase inhibitors such as bictegravir. Their study aimed at defining
the genotypic and phenotypic resistance profiles of BIC and other integrase inhibitors
in highly treatment-experienced and multiresistant patients within the Italian PRESTIGIO
registry whose treatment with twice-daily raltegravir (RAL)- or DTG-based regimens
had failed [21]. GeneSeqIN and PhenoSenseIN assays were performed. Twenty-two samples
from 17 patients were evaluated with a median time since diagnosis and duration of
treatment of 20 years. Median viral load and CD4 T cell count were 4.5 log10 copies/mL
and 168 cells/mm3, respectively. Primary integrase resistance substitutions E138A/K,
Y143C/H/R, Q148H, and N155H were present in 14/22 samples together with the G140S
and Q148H mutations in 11/22 samples. All 14 samples showed resistance to elvitegravir
and raltegravir and two to BIC and DTG, the latter two samples showing L74M, E138K,
G140S, and Q148H or L74M, T97A, S119T, E138K, G140S, Y143R and Q148H substitutions.
Intermediate resistance was reported for 8/14 isolates for BIC and 9/14 isolates for
DTG. Median fold-change (range) values were: BIC 3.1 (0.6–66), DTG 6.1 (0.8–>186),
elvitegravir >164 (2.6–>164), and raltegravir >188 (2.7–>197) in the
14 samples.
Data from another team of Italian investigators by Saladini and colleagues described
the in vitro activity of DTG/BIC/elvitegravir/CAB on first-generation integrase inhibitor-resistant
HIV-1 in plasma samples of 19 patients with major INSTI mutations [22]. The integrase
inhibitors DTG, BIC and CAB showed comparable activity with the Q148H in addition
to one or two mutations to integrase inhibitors associated with decreased susceptibility
for all drugs tested. Data indicates that the Q148H mutation pathway in those in whom
raltegravir was failing appeared more detrimental to the use of second generation
INSTIs than when elvitegravir was failing.
Pregnancy
Since the report of a significant increase of neural tube defects (four cases) from
the Botswana Tsepamo cohort in women exposed to the drug at conception but not later
in pregnancy, there were several reports on the use of other integrase inhibitors
during pregnancy and a review of several cohorts.
Further data from the Tsepamo cohort are awaited and should be available in 2019 with
a report on 1400 pregnancies. Several databases have not clearly highlighted a relationship
between the use of integrase inhibitors and neural tube defects. Two studies that
have compared the use of efavirenz to integrase inhibitors during pregnancy, using
raltegravir- and DTG-based ART regimens, have been shown to be both virologically
superior to the efavirenz-based regimen in pregnant women [23-27].
Contraception
Issues of drug–drug interaction remain paramount in the case of contraception. Previous
reports have highlighted that efavirenz decreases levonorgestrel concentration in
subdermal implants with unintended pregnancy as a consequence. It was disappointing
to learn that doubling the levonorgestrel dose from 150 mg to 300 mg did not overcome
this interaction [28-31]. Double-dose levonorgestrel implants do not fully overcome
the interaction with efavirenz but it is not clear if this double-dose would be able
to prevent pregnancies.
STIs
There was an impression of a déjà vu when Jeanne Marrazzo (University of Alabama,
Birmingham, USA presented on ‘Resurgent sexually transmitted infections (STIs) in
HIV care and prevention’ [32]. Dr Marrazzo started by talking about the dramatic explosion
of STIs (
www.cdc.gov/std; [33,34]. Indeed, it is not just the burden of these infections that
is of concern, but also their characteristics, such as antimicrobial resistance to
treatment for gonorrhoea (24% of countries reported decreased susceptibility to ceftriaxone,
81% to azithromycin [35]), the incidence of syphilis that is above the pre-AIDS era
estimates (153% increase compared to 2013 [36]), the collision with methamphetamines
using networks, the re-emergence of hepatitis C and the reappearance of classics such
as LGV rectitis (TD 05). But what about the role of STIs in ‘Getting to Zero’? For
some, STI burden and scaling up PrEP is independent from HIV incidence [37,38], and
for others, further drivers of HIV spread, including economic and gender inequality,
have to be considered [39-42]. In this context, it would be useful to deploy rapid
and accurate diagnostic tests particularly in high HIV incidence settings, to establish
STI screening in asymptomatic people, and to recognise the pattern of STIs in the
context of HIV.
Comorbidities
ART-associated comorbidities, such us weight gain also occupied a particular place
in CROI. The TD-08 Themed Discussion Session was inaugurated by Jordan E Lake (University
of Texas at Houston, Houston, TX, US) who presented weight gain assessment following
switch to INSTI-based ART among 972 AIDS Clinical Trials Group (ACTG) participants
in ACTG protocols A5001 and A5322 (68% from PI, 31% NNRTI, 2% other non-INSTI at median
7.8 years after parent trial entry) [43]. Median age at switch was 50 years, CD4+
T cell count 511 cells/mm3 and BMI 26.4 kg/m2; 539 switched to RAL, 222 to EVG and
211 to DTG. In adjusted models, white or black ethnicity, age ≥60 and BMI ≥30 kg/m2
were associated with greater weight gain following switch among women, whereas age
≥60 was the greatest risk factor among men.
Kassem Bourgi (Vanderbilt University, Nashville, TN, USA) presented results of weight
changes after initiating ART among treatment-naïve people living with HIV in the North
American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)[44]. Among 4112
individuals initiating INSTI-based regimens between 2007 and 2016 (2106 RAL, 1510
EVG and 477 DTG), weight gain was greatest among individuals starting INSTI. At 2
and 5 years, individuals on INSTI gained 4.4 and 5.8 kg, respectively, compared to
3.3 and 4.1 kg for those taking NNRTIs (P<0.001), and 4.3 and 5.0 kg for those on
PIs (P=0.68), but the mechanisms of these differences are poorly understood.
Grace A McComsey (Case Western Reserve University, Cleveland, OH, USA) described the
demographic, clinical and treatment characteristics of treatment-experienced adults
with virally suppressed HIV who had ≥3% annual weight gain in recent years (2013–2018)
and who were within an observational retrospective study of US clinical practice [45].
In total, 3468 patients were followed-up for a median time of 19 months. Among them,
1045 participants had ≥3% annualised weight gain and when compared to the other 2423
patients they had higher proportions of underweight and normal BMI at baseline, female,
age <50, and psychiatric disorders and lower rates of comorbidities CKD, CVD, DM,
hyperlipidaemia and hypogonadism. In this multivariable logistic regression analysis,
the authors did not see that INSTI use was independently associated with weight gain,
suggesting that, in this population, weight changes are primarily driven by other
factors.
Anne Marie Kerchberger (Emory University, Atlanta, GA, USA) highlighted results of
the Women's Interagency HIV Study (WIHS) that evaluated change in body weight, body
measurements and blood pressure in virologically suppressed women living with HIV
(WLHIV)[46]. Women who switched to or added an INSTI to ART (SWAD group) were compared
to women who remained on non-INSTI ART (STAY group). In total, 1118 WIHS participants
(884 STAY and 234 SWAD) were followed for an average of 2.0 (+/− 0.1) years. Mean
baseline age was 48.8 (+/− 8.8) years. In this population INSTIs were associated with
significant increases in body weight, body mass index, body circumference measurements
and blood pressure over a short period time. No significant differences in outcomes
were observed by INSTI type.
Raphael J Landovitz (University of California Los Angeles, CA, USA) presented the
first results of cabotegravir studies regarding weight gain under a regimen containing
this molecule [47]. HPTN 077, a Phase 2a randomised placebo-controlled study of two
dose/dose-interval regimens of cabotegravir, enrolled 199 HIV-uninfected participants
from eight sites in the US (4), Brazil (1) and sub-Saharan Africa (3). Median weight
change over 41 weeks was +1.1 kg (IQR -0.9–3.0) in the CAB arm and +1.0 kg (IQR -1.2–3.2)
in the placebo arm (P=0.66). In longitudinal statistical analyses, no statistically
significant differences were found in change in weight from weeks 0 to 41 in CAB-
versus placebo-treated participants in aggregate, by sex, dosing cohort, age, race/ethnicity,
smoking status, BMI, nor by baseline BMI category. Changes in fasting glucose and
fasting lipids from weeks 0 to 41 were not different between CAB and placebo. This
analysis suggests that CAB may have different effects on weight/weight gain than dolutegravir.
Sara H Bares (University of Nebraska Medical Center, Omaha, NE, USA) explored changes
in immune activation following ART initiation in two large randomised ACTG trials
(A5202 and A5257)[48]. In total, 340 participants were selected with a median pre-ART
age 42 years, CD4 cell count 273 cells/mm3, HIV-1 RNA 4.7 log10 copies/mL; 49% were
women, 33% white, 42% black and 24% Hispanic. While pre-ART BMI was similar between
gainers and maintainers (overall and within sex), gainers had significantly lower
pre-ART CD4 cell counts versus maintainers. In adjusted models among those with normal
pre-ART BMI, pre-ART IL-6, sTNF-RII, IP-10 and sCD163 were higher for gainers versus
maintainers. Association of weight gain on week 96 changes of these four biomarkers
differed by sex: women who gained weight had smaller declines in biomarkers compared
to men who gained. In total, higher pre-treatment immune activation markers are significantly
associated with weight gain following ART initiation even after controlling for pre-ART
CD4 counts. Weight gain attenuates the decline in several immune activation markers
following ART initiation among women; thus, women may be at increased risk for complications
of weight gain.
Cardiac morbidity was at the heart of communications regarding ‘Non-communicable Diseases
in treated HIV’. Kristina Crothers (University of Washington, Seattle, WA, USA) assessed
25,509 people living with HIV of the CFAR Network of Integrated Clinical Systems (CNICS)
cohort for COPD and myocardial infarction (MI) risk [49]. COPD was associated with
a significantly increased risk of MI (adjusted hazard ratio [aHR] 2.09, 95%CI 1.50–2.91)
even after adding smoking (aHR 1.88, 95%CI 1.34–2.63). Matthew Freiberg (Vanderbilt
University, Nashville, TN, USA) analysed data on 144,362 veterans (30% living with
HIV) from the Veterans Aging Cohort Study (prospective study of veterans living with
HIV and age, sex, race/ethnicity and clinical site matched veterans without HIV) in
terms of risk of sudden cardiac death (SCD)[50]. In this analysis and after adjustment
for confounders, veterans living with HIV had a 14% higher risk of SCD (hazard ratio=1.14,
95% CI 1.04–1.25) compared to veterans without HIV. The risk was highest among those
with sustained high HIV viral loads or low CD4 cell counts.
Linda Ann Battalora (Colorado School of Mines, Golden, CO, USA) calculated mortality
rates over 17 years in a longitudinal prospective observational cohort (HOPS, HIV
OutPatients Study) currently conducted in six US cities, which is also evaluating
the association of bone fractures with mortality [51]. Among 6826 HOPS participants
followed for a median of 6.2 years, 502 (7%) had incident fracture recorded and 729
(10%) had died. Median age at fracture was 48 years (interquartile range 41–55 years).
Of patients, 16.5% with major osteoporotic fractures died (crude mortality 1.5 per
100 person-years [py]), while 14.6% with fractures at other sites died (crude mortality
1.3 per 100 py). In multivariable analysis, incident fracture was significantly associated
with all-cause mortality (Hazard ratio 1.5, 95% CI 1.2–1.9) as were multiple other
factors, notably nadir CD4 cell count <200 cells/mm3, non-AIDS cancer, hepatitis C
infection and chronic liver, renal and cardiovascular disease comorbidity.
Prevention
Sharon L Hillier (Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA) gave an interesting
update on HIV prevention during the Committee Workshop for New Investigators and Trainees
[52]. She said that even if new HIV infections have declined by 51–76% since the start
of PEPFAR, the success in HIV epidemic control is disproportionate by age group or
belonging or not to a minority group, and rates of HIV in Africa still are eight times
higher than in the US and 10 times higher than in Europe.
There is a terrible mismatch between people in real need for PrEP and people who finally
get it. In terms of PrEP, the Phase-3 DISCOVER study [53] was a randomised (1:1),
double-blind, active-controlled study conducted in North America, Canada and Europe
in cis-men who have sex with men (MSM) and transgender women (TGW) who are at high
risk of HIV acquisition. The objective was to describe the efficacy and safety of
FTC/TAF versus FTC/TDF for PrEP. A total of 5387 adults was treated at 94 sites in
11 countries, with a mean age of 34 years, range 18–76 years, 9% black, 2% TGW, 25%
had prior PrEP use and 41% had more than three receptive condomless anal sex partners
in the 90 days before study entry. The HIV incidence rate on either FTC/TAF or FTC/TDF
was very low and significantly less than the background rate in those at risk but
not on PrEP in the US. In almost 2 years of follow up, both FTC/TAF and FTC/TDF, given
daily, were tolerated and had low discontinuation rates. The primary endpoint analysis
reported an HIV incidence of only 22 HIV infections across both arms diagnosed over
8756 py of follow-up. The incidence rate ratio was 0.47 (95% CI 0.19–1.15) establishing
non-inferiority of FTC/TAF to FTC/TDF for HIV prevention.
Even though the effectiveness of PrEP in real life has been even better than in clinical
trials [54], failures were reported in a context of increased and/or improper use
[55,56]. Screening difficulties for instance, may expose non-reactivity of the fourth-generation
assay that can reach 18% in acute infection in some studies [57].
PrEP failures have many causes, such as ambiguous HIV screening test results. System
failures refer to the lack or limited access to PrEP because of unavailability, lack
of awareness among people at risk and healthcare providers and cost. Doctors’ failures
refer to insufficient knowledge of PrEP with the failure to rule out HIV infection
when starting or renewing PrEP, or reluctance to prescribe PrEP. People failures are
mostly due to the deferred or improper use of PrEP. Assay failures refer to the challenges
of HIV diagnosis due to the low sensitivity of HIV tests during the first days/weeks
following HIV acquisition. PrEP failures can lead to drug resistance when PrEP is
started or maintained in a person who has acquired HIV. In clinical trials, most cases
of HIV infection with resistance occurred when PrEP was started in someone with undiagnosed
HIV infection. Overall, true biomedical failures of PrEP remain rare.
The much expected results of the HPTN 071 (PopART) trial were presented [58].
The primary result of the trial was presented by Professor Richard Hayes (London School
of Hygiene and Tropical Medicine). The HPTN 071 (PopART) trial was designed to see
whether delivering a door-to-door combination package including HIV testing, linkage
to treatment and prevention could achieve high coverage of ART in people living with
HIV such that the number of new HIV infections would be reduced compared with current
standard of care approaches. The study design was as follows: one million people living
in 21 urban communities in South Africa and Zambia agreed that their community would
participate in this study. The 21 communities were randomly allocated to one of three
approaches matched into triplets by the baseline levels of HIV prevalence. Seven communities
allocated to arm A of the trial were offered community-wide HIV combination prevention
approach, seven arm B communities were offered the same household-based HIV testing
and education but, in these communities, antiretroviral treatment (ART) was offered
in line with current national guidelines and seven arm C communities received the
current standard-of-care approach to HIV testing prevention and treatment. ART was
available through routine government HIV clinics in all 21 communities irrespective
of study arm. The PopART intervention included all HIV care, ART and prevention was
offered to every resident within all 21 communities involved in the trial by government
partners at the local healthcare facilities. This continued in the standard-of–care
arm C communities, and changes in national guidelines and policy for ART initiation
changed through the lifetime of the trial and were implemented in accordance with
local recommendations. ART initiation guidelines changed during the study period to
the offer of universal ART irrespective of CD4 cell counts by 2016. In addition to
the routine government healthcare facility provision of HIV testing, prevention and
treatment, the PopART intervention employed a new cadre of staff: community HIV care
providers, referred to as ‘CHiPs’. CHiPs were lay counsellors specially trained to
work through every household within a community on an annual basis offering HIV counselling,
testing, prevention and treatment, provision of condoms, TB screening and testing,
and sexual and reproductive health tests. In any cases requiring medical care and
treatment, CHiPS teams encouraged and supported HIV-positive clients to attend and
remain in care at government
healthcare clinics.
In terms of the primary outcome, the number of new HIV infections in each community
was measured over the study period (2014–2018) in a separately recruited randomly
selected cohort of approximately 20,000 individuals per community who consented to
have a blood test taken annually for
HIV testing.
The main outcome of the trial was to compare HIV incidence by study arm over the time
of the trial (between 2014 and 2018); arms A versus C and arms B versus C. This was
done based on blood collected from the research cohort. Results show that the intervention
overall reached the UNAIDS 90-90-90 targets, and viral suppression among people living
with HIV increased in the intervention arms from a baseline of approximately 55% to
over 70% by the end of the trial period. This resulted in a 30% decline in new HIV
infections in communities where HIV prevention, including home-based HIV counselling
and testing, was provided, as well as referral to HIV care and treatment for people
testing positive for HIV according to country guidelines (arm B). This finding is
highly statistically significant. There was a much lower reduction in HIV incidence
(7%) comparing arm A communities with arm C that was not statistically significant.
The lack of impact in arm A communities is difficult to explain at present. Ongoing
analyses are exploring this further. A post hoc analysis combining the impact of arms
A and B versus C demonstrated an overall statistically significant reduction in HIV
incidence of 20%. Overall this trial showed that community-wide services can enhance
the coverage of knowledge of HIV status and ART coverage to a level that leads to
significant reductions in
HIV incidence.
Hepatitis C
Jürgen K Rockstroh (University of Bonn, Germany) described dynamics of acute HCV in
Western Europe [59]. With the advent of highly successful and well tolerated direct
acting antiviral (DAA) combinations, HCV elimination appears to be a reachable goal.
The Global Health Sector Strategy (GHSS) calls for the elimination of viral hepatitis
as a public health threat by 2030 (reducing new infections by 90% and mortality by
65%). Nevertheless, major obstacles have to be overcome in order to approach HCV elimination,
namely underdiagnosis (only 20% of people with HCV worldwide having been diagnosed
so far) and insufficient treatment uptake (among 71 million people that were thought
to be infected with HCV in 2015, only 1.76 million people received HCV treatment in
2016). Additionally, although national studies from the Netherlands and Switzerland
show a significant 50% reduction in the incidence of newly acquired acute HCV infections
by increasing treatment uptake for MSM with HIV and HCV co-infection, current HCV
outbreaks and the risk of HCV re-infections clearly weakens this success. Earlier
HCV treatment initiation and earlier acute HCV diagnosis will be needed in order to
impact HCV dynamics.
Lucy Garvey (Imperial College Healthcare NHS Trust, London, UK) described HCV incidence
kinetics in MSM living with HIV in London following wider access to DAA therapy [60].
While BHIVA aims to cure HCV co-infections in 100% by 2021, modelling work predicts
that significant scale-up of HCV treatment will be important [61]. Using real world
experience, Sanjay Bhagani's group examined trends in incidence of acute HCV between
2013 and 2018 in three central London HIV clinics in MSM living with HIV, who constitute
a potential target for microelimination. In total, 256 acute HCV diagnoses were identified,
of which 45 were reinfections. The median age was 43 years and 85% were virologically
suppressed. Incidence of first HCV episode peaked at 15/1000 (95%CI 10–19) person-years
of follow upin 2015. Rates declined by 79% by 2018 with no change to screening practices.
Re-infection rates increased from 9% to 47% during the study period. Patients diagnosed
with acute HCV during the study period most likely awaited chronic infection to receive
DAAs via the NHS (for an average of 23 months following diagnoses), while the majority
of individuals received treatment via a clinical trial in more recent years (average
of 10 months). Time from diagnosis to starting any HCV treatment reduced from an average
of 40.9 months (2013) to 3.1 months (2018).
Adeel A Butt (Pittsburgh Healthcare System, PA, USA) presented results about the impact
of newer DAA regimens upon subsequent incidence and risk of diabetes comparatively
to untreated and pegylated interferon/ribavirin (PEG/RBV)-treated controls within
the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES)[62]. Researchers
identified 4764 PEG/RBV-treated, 21,279 DAA-treated, and same number of untreated
controls. Diabetes incidence rate (95% CI)/1000 person-years of follow up were 19.8
(18.3–21.4) among PEG/RBV- and 9.89 (8.7–11.1) among DAA-treated persons (P<0.001).
Among the treated, rates were 13.3 (12.2–14.5) for those with sustained virological
response (SVR) and 19.2 (17.4–21.1) for those without SVR (P<0.0001). Treatment was
associated with a larger reduction in incident diabetes rate in persons with more
advanced fibrosis/cirrhosis (absolute difference 2.9 for FIB-4 <1.25; 5.7 for FIB-4
1.26–3.25; 9.8 for FIB-4 >3.25). DAA treatment (HR 0.48, 95%CI 0.42–0.56) and SVR
(HR 0.81, 95%CI 0.70–0.93) were associated with a significantly reduced risk of diabetes,
and may therefore be useful in mitigating some of the extrahepatic
complications of HCV.
In the context of growing incidence of hepatocellular carcinoma (HCC) in people living
with HIV since 1996, Jessie Torgensen (University of Pennsylvania, Philadelphia, PA,
USA) conducted a cohort study within the VACS in order to determine the impact of
HIV and CD4 cell count on HCC risk [63]. They identified 278 incident cases of HCC,
with a median age of 56 years, and what was striking is that 43% (95% CI 37–49%) of
patients at the time of HCC diagnoses had no markers of advanced hepatic fibrosis/cirrhosis
by FIB-4 (FIB-4 <3.25), which is in contrast with the general population where 13%
of HCC occur without cirrhosis. Among these patients, there is a higher proportion
of morbid obesity (BMI>30 kg/m2) and diabetes and chronic hepatitis B were independently
associated with incident HCC. In multivariable models, among patients with baseline
FIB-4 >3.25, only chronic hepatitis B and C increased the risk of HCC development.
In contrast, among patients with low baseline markers of hepatic fibrosis/cirrhosis
(FIB-4 <3.25), HIV and CD4 cell count were also as significant as chronic hepatitis
B and C. Specifically, there was a 24% increased risk of HCC for every one log increase
in HIV viraemia, and a 57% increased risk of HCC for people with more than 11 months
of detectable viraemia.
Catherine Anne Chappell (Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA) presented
a pilot study about the safety of and virological response to ledipasvir 90 mg/sofosbuvir
200 mg (LDV/SOF) therapy in pregnancy [64] in the context of the ongoing hepatitis
C virus epidemic among young people in the US, including pregnant women (200 women
per year)[65,66]. Seven women were enrolled, all of whom were white, with a median
age of 32 (range 25–38) years and a median HCV viral load at enrolment of 518,173
(range 103,457–3,757,923) copies/mL. All had a rapid response to therapy and all achieved
SVR-12. All adverse events related to LDV/SOF were ≤grade 2. All seven participants
delivered at term with undetectable HCV viral loads at delivery. One-year follow-up
of infants is ongoing, but these results suggest that viral response is similar to
non-pregnant individuals.